Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ARTV
Upturn stock ratingUpturn stock rating

Artiva Biotherapeutics, Inc. Common Stock (ARTV)

Upturn stock ratingUpturn stock rating
$1.51
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $15.4

1 Year Target Price $15.4

Analysts Price Target For last 52 week
$15.4Target price
Low$1.47
Current$1.51
high$17.31

Analysis of Past Performance

Type Stock
Historic Profit -19.34%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 35.81M USD
Price to earnings Ratio -
1Y Target Price 15.4
Price to earnings Ratio -
1Y Target Price 15.4
Volume (30-day avg) 6
Beta -
52 Weeks Range 1.47 - 17.31
Updated Date 06/29/2025
52 Weeks Range 1.47 - 17.31
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.04

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -33.3%
Return on Equity (TTM) -68.14%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -115422322
Price to Sales(TTM) 214.51
Enterprise Value -115422322
Price to Sales(TTM) 214.51
Enterprise Value to Revenue 7.54
Enterprise Value to EBITDA -
Shares Outstanding 24363100
Shares Floating 5916827
Shares Outstanding 24363100
Shares Floating 5916827
Percent Insiders 19.99
Percent Institutions 89.73

Analyst Ratings

Rating 3
Target Price 15.4
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Artiva Biotherapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Artiva Biotherapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing allogeneic natural killer (NK) cell therapies to treat cancer. Founded in 2019, Artiva is advancing a pipeline of off-the-shelf NK cell therapies designed to be readily available and scalable to address significant unmet needs in oncology.

business area logo Core Business Areas

  • Allogeneic NK Cell Therapies: Develops and commercializes allogeneic, or off-the-shelf, NK cell therapies for cancer treatment. This includes cell engineering and manufacturing processes.
  • Partnered Programs: Collaborates with pharmaceutical companies to develop and commercialize NK cell therapies targeting specific cancer indications.

leadership logo Leadership and Structure

The leadership team is composed of experienced biopharmaceutical executives with backgrounds in cell therapy development and commercialization. The organizational structure includes research and development, manufacturing, clinical development, and business development functions.

Top Products and Market Share

overview logo Key Offerings

  • AB-101: An off-the-shelf, cryopreserved, allogeneic NK cell therapy candidate being developed for the treatment of relapsed or refractory B-cell lymphomas. Competitors include other companies developing allogeneic cell therapies, such as Fate Therapeutics and Nkarta. Currently in Phase 1/2 clinical trials, therefore market share data and revenue figures are not currently available.
  • AB-102: AB-102 is another NK cell therapy candidate engineered with CAR (chimeric antigen receptor). Preclinical trials are underway. Revenue figures and market share data are not currently available. Competitors include other companies developing allogeneic cell therapies, such as Fate Therapeutics and Nkarta.

Market Dynamics

industry overview logo Industry Overview

The cell therapy industry is rapidly growing, driven by increasing demand for innovative cancer treatments. Allogeneic cell therapies offer advantages over autologous therapies, including scalability and reduced manufacturing costs.

Positioning

Artiva is positioned as a leader in the allogeneic NK cell therapy space, with a focus on developing scalable and readily available therapies. Their competitive advantage lies in their proprietary manufacturing platform and strategic partnerships.

Total Addressable Market (TAM)

The total addressable market for cell therapies in oncology is estimated to be in the tens of billions of dollars annually. Artiva is positioning itself to capture a significant share of this market through its innovative NK cell therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary NK cell therapy platform
  • Scalable manufacturing process
  • Strategic partnerships with pharmaceutical companies
  • Experienced management team

Weaknesses

  • Early stage clinical development
  • High cash burn rate
  • Dependence on strategic partnerships
  • Limited commercial experience

Opportunities

  • Expanding clinical trials into new indications
  • Securing regulatory approvals for lead product candidates
  • Expanding strategic partnerships
  • Advancing manufacturing capabilities

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other cell therapy companies
  • Manufacturing challenges

Competitors and Market Share

competitor logo Key Competitors

  • NKarta, Inc. (NKTX)
  • Fate Therapeutics (FATE)
  • Gamida Cell Ltd. (GMDA)

Competitive Landscape

Artiva competes with other cell therapy companies developing allogeneic NK cell therapies. Their competitive advantage lies in their proprietary platform, scalable manufacturing process, and strategic partnerships. They are in the development stage and not yet generating revenue.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by investment in research and development, clinical trial progress, and securing strategic partnerships.

Future Projections: Future growth is dependent on the successful development and commercialization of NK cell therapies. Analyst estimates vary based on clinical trial outcomes and regulatory approvals.

Recent Initiatives: Recent initiatives include advancing clinical trials for lead product candidates, expanding manufacturing capabilities, and exploring new strategic partnerships.

Summary

Artiva Biotherapeutics is a promising clinical-stage biopharmaceutical company focused on allogeneic NK cell therapies. It has a proprietary platform and strategic partnerships but is still early in its development. Successful clinical trials and regulatory approvals are key to its future growth, but also potential risks that could result in significant loss. The competition is heating up and there are many companies also working on cell therapies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Artiva Biotherapeutics, Inc. SEC Filings
  • Company Website
  • Analyst Reports
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Artiva Biotherapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2024-07-19
President, CEO & Director Dr. Fred Aslan M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 96
Full time employees 96

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.